To include your compound in the COVID-19 Resource Center, submit it here.

VEGF Trap-Eye aflibercept ophthalmic solution: Phase III data

Top-line data from the double-blind, international Phase III GALILEO trial in 172 patients with macular edema due to CRVO showed that monthly 2 mg intravitreal VEGF Trap-Eye met the primary endpoint of a significantly greater proportion of patients whose BCVA improved

Read the full 413 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE